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ABSTRACT 
 
G-protein coupled receptors (GPCRs) are currently the largest class of 
membrane receptors and are targeted by a majority of the modern drug 
therapeutics. In addition, they partake in many physiological and pathological 
processes such as inflammation, growth, and hormone responses. Most 
importantly, GPCRs are targets of many disease-specific pathways such as 
Alzheimers, hypertension, leukemia, and depression. As a result, there is an 
immense interest in studying GPCRs as this area provides further knowledge into 
the specific disease pathways and allows the discovery of novel therapeutics. In 
order to have a better understanding of pathways, scientists have studied GPCR 
activation. The prostanoid receptors are of great interest because they 
coordinate a vast range of physiological processes such as regulating 
cardiovascular pathways, modulating neuronal activity and controlling immune 
responses. We collaborated with Multispan Inc., a biotech company focusing 
exclusively on drug discovery research targeting GPCRs, to monitor the agonist-
induced internalization of GPCRs from the prostanoid family through live cell flow 
cytometry. From our experimental results, we have observed over 50 percent 
internalization for the EP1 and EP4 receptors within 60 minutes after being 
activated by iloprost and PGE2 respectively. Our initial experimental results have 
also shown over 40 percent internalization for the TP receptor within 120 minutes 
after exposure to PGD2. Overall, we have been able to utilize Multispan’s 
proprietary cell lines to overexpress a few of the prostanoid receptors. These 
assays are powerful tools for the discovery of novel therapeutics, as they enable 
the testing against libraries and screening from a few thousand to a few million 
compounds.  
 
Keywords: GPCR, prostanoid, agonist, internalization, flow cytometry, iloprost, 
PGE2 
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1.0 INTRODUCTION 
1.1 Background/Motivation 
G-protein coupled receptors (GPCRs) are the largest and most diverse class of 
membrane receptors. One of the main functions of GPCRs is to trigger 
secondary messengers such as cyclic adenosine monophosphate (cAMP) or 
calcium ion channels. The activation of the secondary messengers helps 
regulate body functions such as sensation, growth and hormone responses.1 In 
order to trigger secondary messengers, the GPCR must be activated by the 
binding to a ligand. As a result, there is an immense interest in studying the 
specific pathways of GPCRs.  GPCRs also have an extremely large market of 
about $122 billion by 2018. Currently, over 250 GPCRs have been identified and 
150 GPCRs to de-orphanize, which presents a tremendous opportunity for future 
research.2 The biggest motivation for GPCR research is that they are responsible 
for many disease-specific pathways such as endocrine and vision disorders.3 As 
a result, the industry has a demand for better therapeutic discovery tools, such 
as assays, as a new platform for monitoring receptor activation. These new 
platforms would lead to a better understanding of the disease pathways. By 
developing a better understanding of disease pathways, researchers will be able 
discover novel therapeutics for the treatment of these diseases. Please refer to 
the glossary of terms in  
 
1.2 Project Goals & Objectives  
Our aim is to develop quantitative measurements of receptor response for novel 
therapeutics. This is done first through the development of assays to measure 
the internalization of GPCRs. The process of internalization begins when the 
GPCR is activated through the binding of a specific ligand at the site by the N-
terminus. By measuring the EC50 values for internalization for each specific 
GPCR, we can better understand an entirely new platform of receptor activation. 
In addition to EC50 values, we must obtain the specific time intervals at which 
internalization occurs. By obtaining these key pieces of information, we hope to 
establish new internalization assays using Multispan Inc.’s existing platforms. As 
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Figure 1: Schematic showing the different steps in 
clathrin-coated endocytosis 
interns at Multispan Inc., we are responsible for developing assays for the 
GPCRs within the prostanoid family. Our aim is to obtain valid EC50 values for 
the activation of these two families of GPCRs. EC50 values must be reproducible 
within three folds of each other. If the previous goals are achieved, our future 
goals would be to perform antagonist testing to inhibit the internalization of the 
GPCRs. If the previous two tasks are accomplished we can then use this 
platform to test against pharmacological libraries for novel therapeutics.  
 
1.3 Review of Field/Literature 
The following paragraphs contain our literature findings on the general structure 
of GPCRs and the specific functions and diseases associated with prostanoid 
receptors. In addition, we researched on the ligands that have been used for 
specific GPCRs for other assays such as calcium and cAMP assays. These 
findings helped us in our agonist selection along with targeting the time frame for 
running these experiments. Most importantly, our literature research helped us 
select the GPCRs with the highest chance to internalize with the available 
agonists that we have.  
 
1.3.1 General Structures of GPCRs  
GPCRS are composed of seven hydrophobic transmembrane domains which 
include an extracellular 
amino terminus and an 
intracellular carboxyl 
terminus. A ligand 
binding domain, located 
close to the extracellular 
amino terminus, causes 
the activation the GPCR 
when a ligand binds to  
the region.4  
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The process of internalization occurs when a ligand binds to the GPCR. Clathrin-
dependent GPCR internalization occurs when an agonist binds to the receptor 
and triggers conformational change because it transforms the receptors into 
substrates of the GRKs. The GPCRs that are occupied by the ligand become 
phosphorylated and at the cytosolic Serine and Threonine residues. The 
phosphorylated ligand-complex then rapidly recruits β-arrestins which disrupts 
further signaling to the G proteins. β-arrestins then promote clathrin-dependent 
endocytosis by binding to the GPCR with adaptor proteins to form the early-
coated pit. As illustrated by Figure 1, more clathrin and adaptor proteins continue 
to accumulate and the clathrin-coated pit detaches from the plasma membrane 
with the addition of dynamin. The ligand-receptor clathrin complex then 
internalizes and travels along the internalization pathway. The clathrin and 
adaptor proteins then uncoat from the complex and from this point, at least two 
possibilities exist; the receptors are either removed from ligands and recycled 
back to the cell surface or the receptors are transferred to late endosomes which 
readied them for lysosomal degradation.5 
 
1.3.2 Prostanoid Receptors  
Prostanoid receptors are part of a family of active lipids which can be further 
divided into three main groups: prostaglandins, prostacyclins, and thromboxanes. 
They are sometimes referred to as local hormones which act in an autocrine 
manner to control the effects of other hormones in the circulation. They 
coordinate a vast range of physiological processes which ranging from producing 
cardiovascular effect to modulating neuronal activity, and controlling inflammation 
and immune responses. The receptors express their activity by interacting with 
G-protein-linked receptors divided into five classes. PGE2(EP1 through EP4), 
PGD2 (DP1 and DP2), PGF2α (FP), PGI2 (IP) and TXA2 (TP). The initial effect in 
activating these receptors is the increase or decrease in the uptake rate of cAMP 
or calcium ions. The activation of the receptor further translates into regulating 
the physiological and pathological processes of the body.6 The disease pathways 
associated with prostanoids include: atherothrombosis, aortic aneurysm, cancer, 
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hypertension, and leukemia. An example of how prostanoid receptors may play a 
direct role in cancer is displayed in mice model. Mice models lacking EP1, EP2, or 
EP4 have a lower chance of disease in carcinogenesis models.
7  
 
1.3.3 Selection of agonists for prostanoid receptors  
Our approach towards agonist selection would be to research on other assays 
that have been done for the specific receptor. Prostaglandin E2 (PGE2) has been 
found to be an effective agonist to trigger internalization for the EP4 receptor. In 
fact, it has been observed that there is about 20 percent internalization for HEK 
293-EBNA-HA-hEP4 transfected with dominant negative β-arrestin 1. In addition, 
1µM of PGE2 was used over the course of 60 minutes.
8 Although the specific cell 
line is different along with the transfected components, these are great starting 
points to construct our internalization assay for EP4 receptor. EP1 and IP 
receptors have been found to have an extremely high binding affinity for iloprost. 
High binding affinity may potentially play a large role in internalization as the 
experiments within an article by Whittle et al., has tested the EC50 values for 
cAMP and calcium assays. On the other hand, iloprost has a low affinity for FP, 
EP3, and EP4 receptors.
9 PGD2 has been found to be an effective agonist for DP1 
and DP2.
10 In addition, the potency of the agonists found above has been 
validated through the IUPHAR database.  
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2.0. SUBSYSTEM CHAPTERS  
 
 2.1. Technology Overview 
 
 
 
 
 
Our experiment is composed of several components: receptor and ligand 
selection, incubation, subsequent washes, antibody staining, and analysis of 
under the flow cytometer. Serial dilutions are performed to prepare the drug 
compounds and a detailed description can be found in chapter 3.1. The drug 
compounds are then incubated in 37 degrees Celsius with the cells 
overexpressing the receptor of interest and then subsequent washes are 
performed. The cells are then stained with the anti-FLAG tag antibody and 
incubated for 30 to 60 minutes. More subsequent washes are performed and the 
cells are resuspended in FACS buffer and ready for analysis under the flow 
cytometer. The data obtained is then analyzed in Graph Prism 4 to create the 
EC50 plots.  
 
2.3 Customer Needs and Requirements  
2.3.1. Company Needs 
When we first started the assay development, we realized that Multispan Inc., 
was the customer who we need to prioritize first because we knew very little 
about the technology and the product market. As a result, we interviewed three 
Figure 2. A linear flow diagram illustrating the technology and processes 
involved in the entire experiment. First, the receptor of interest is chosen 
and then the ligand potent to the receptor is incubated with the cells 
overexpressing the desired receptor for a given amount of time. Next, 
subsequent washes are performed and the cells are stained with anti-FLAG 
tag antibodies. After antibody staining, the cells are ready for analysis under 
the flow cytometer.  
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different individuals within the company and created three different 
questionnaires which can be found in Appendix A. Instead of sending out e-
mails, we interviewed each one individually so that we immediately clarify our 
questions if they are unclear. They individuals from the company range from 
different areas of specialties such as research and development, management 
and sales.  
 
We first interviewed our industry advisor and Multispan Inc’s CEO, Dr. Helena 
Mancebo. Her feedback would lead us to our main task and what is expected 
from our team. In addition, we would find out what we need to do to address the 
needs of Multispan Inc’s customers. Dr. Helena Mancebo provided us with the 
following information:  
 
Currently, there is not a direct competitor offering the same internalization assays 
as Multispan Inc. The results of each internalization assay must be reproducible 
with less than 3 fold differences for EC50s for IC50s in 3 independent 
experiments for it to be considered “validated.” There is a need to develop 
validated internalization assays for all targets within each assigned receptor 
family. 
 
The second individual who is interviewed was Dr. Ricai Han, who was the Senior 
Scientist at Multispan Inc. Although Dr. Han has not directly worked with 
Prostanoid receptors, he was able to provide us with some of his insights from a 
researcher’s perspective. According to Dr. Han, Multispan Inc, is unaware of the 
affinity of the receptor or any other specific information regarding the drugs sent 
by companies such as Johnson and Johnson for testing. They also do not know 
which compound could trigger signal transduction from the GPCR. In order to 
perform internalization assays on these drugs the researcher must characterize 
the function and the activities of how it could affect surface expression in addition 
to finding the internalization factor. Without performing the previous steps, it 
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would be extremely difficult to select for the most suitable GPCR that the drug 
acts upon.  
 
Finally, we interviewed Dr. Radhika Venkhat, who is the R & D Manager at 
Multispan Inc. Dr. Venkhat has provided us with an entirely different perspective 
as she is the expert in internalization assay at the company. According to 
Radhika, she has worked with internalization many different types of receptor 
and the approach has to be paired with understanding the different properties of 
each specific receptor. She has only worked with DP2 from the family that we are 
assigned to work on. She explains to us that one of the first issues we will face is 
the selection of the specific agonist or antagonists to use for each assay. These 
are chosen based on those reported from literature research and analysis. Some 
may require internalization with other receptors or it is derived from external 
factors. The second issue is the framing the time point of internalization for an 
unknown compound with a receptor. The main reason is that for some receptors, 
there is a rapid recycling time frame for some receptors and it is essential to 
grasp the window of internalization in order for us to not miss it. She advised our 
group to keep practicing on the technique and running the assays as once the 
technique is mastered and we learn more about the theoretical component from 
the literature, we will have a much better understanding on how to set up the 
assays.  
 
2.3.2. Product Design Specification  
Our Product Design Specification is broken into 3 categories: the assay itself, 
confidentiality, and deliverables. A detailed table is provided in Appendix A. The 
assay itself further contains 3 subclasses: EC50 or IC50 (optional) accuracy, 
complete validation of all family receptors, and reproducibility. Confidentiality is 
further divided into 3 subclasses: proprietary procedures, materials and 
information, and IP protection of ligand specifics from pharmaceutical companies. 
The last category is deliverables which includes one subcategory of having 
complete data under final conditions.    
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2.4 Benchmarking Results 
Currently, there are not any known existing products that are similar to the 
internalization assays offered by Multispan. The most significant advantage of 
live cell flow cytometry is that it allows the accuracy of the quantitative analysis to 
go down to counting each individual cell over a specific time period. Currently, 
there isn’t another testing method that is able to provide such accuracy. Although 
this testing method is lengthier compared to the alternatives, the optimum 
accuracy obtained from the measurements makes this a worthwhile tradeoff. 
Other GPCR companies perform assays on different GPCR lines which are not 
screened by Multispan Inc. The testing methods used are also different as none 
of them currently incorporate the same platform with live cell flow cytometry and 
fluorescence tagging as Multispan Inc. Another indirect competitor would be 
virtual drug screening which is extremely promising in that it reduces the costs 
and time for novel therapeutic screening but it requires the assays to be done 
and validated previously. Table 1 below compares the advantages and 
disadvantages of the testing method that Multispan Inc. uses to the other 
available testing methods.   
 
Table 1. Analysis of different testing methods: Table comparing both the 
advantages and the disadvantages between the other available testing methods 
and Multispan Inc.’s testing platform  
Testing Method Advantages Disadvantages 
Multispan’s platform  
Live cell flow cytometry  
Flow cytometry enables 
precision down to each 
individual cell for monitoring 
internalization and provides 
specific time points for 
internalization 
Assay is more time 
consuming for some 
receptors 
Other platforms Often little complex analysis Quantitative results 
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(Infrared fluorescence) involved and direct functional 
read out.  
are not as precise 
down to individual cell 
count.  
Virtual Drug Screening Can cut costs and time and is 
and provide a theoretical result  
This requires a valid 
existing database to 
build on and is not 
effective yet as a 
predictor tool.    
 
2.5 Key System Level Issues 
2.5.1. Main Issues:  
The main issue of the internalization assay system revolves around the 
uncertainty of how the ligand will internalize. Although the selection of the ligand 
is made based upon known publications, the way of which these receptors 
internalized is still unknown. The success of using a particular ligand for different 
assay does not imply that the similar success will carry over for internalization. In 
addition, it is more economical to use the ligands that Multispan Inc. already has 
rather than buying more since it’s not guaranteed that those will work really well. 
To further complicate matters, some G protein-coupled receptors require 
homodimerization or heterodimerization with another receptor in order to 
internalize into the cellular membrane. After figuring out the specific mechanism 
and conditions which triggers a ligand to internalize, the next issue would be to 
pinpoint the time frame at which this event occurs. Some receptors may 
internalize within 5 minutes while others may require a much lengthier period 
such as 3 hours in order for the process to occur. Although an EC50  curve is able 
to guide us into the right time point, knowing the exact window would cut down 
costs and time for the experiments.  
  
2.5.2. System Options: 
Agonist selection: The selection of the agonist is done through researching 
similar experiments which have been performed on the specific prostanoid 
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receptor. We will work on the receptors with known agonists for similar 
experiments first before we move onto the other ones.  
  
Concentration: The concentration of the agonist compound can be varied 
accordingly. A higher starting compound concentration would be used if the 
agonist has a low affinity towards the receptor. If the agonist has a high affinity 
towards the receptor, a low starting concentration would be required.  
 
Specific Time period: The time period of internalization is obtained through 
literature research which contains time intervals for other assays such as 
calcium, and cAMP. For receptors that contain little information a time window of 
2 hours is general accepted.  
 
2.5.3. Tradeoffs: 
Currently, the experiment contains several paramaters which need to be taken in 
consideration as the assays may completely head towards a different direction 
with the inclusion or inclusion of these factors. Table 2 highlights the pros and the 
cons of three options such as cell fixation, flow cytometery, and an economical 
agonist selection.  
 
Table 2. Tradeoffs: Comparison between each process option and the decision 
made in the end with both the pros and cons in consideration 
Option Pros Cons Decision 
Fixing the cells 
with 
paraformaldehyde 
Allows assays 
to be done at 
later time 
Too many cells are 
lost in the process and 
you need to monitor 
the timeframe carefully 
Fixing will not 
be considered 
for experiment 
Live Cell Flow 
Cytometry 
Providing 
analysis down 
to each 
individual cell 
Much more time 
consuming than using 
a plate reader  
Flow cytometry 
will be used 
because of 
accuracy  
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Using alternative 
agonists over the 
most potent ones 
found in literature  
More 
economical to 
use what the 
company has 
first  
Assays may not work 
well with alternatives 
because they are not 
as potent with the 
receptor  
Alternative 
agonists will be 
used first before 
we venture into 
buying the most 
potent ones 
found in 
literature  
 
2.6 Team and Project Management 
2.6.1. Project Challenges and Constraints 
In any group project, challenges and constraints are inevitable but they must be 
taken in consideration and solved before the project can progress. The major 
constraint for most projects is the management of the given budget. Fortunately, 
most of the expensive compounds, cell lines, and reagents were provided by 
Multispan Inc. By communicating with our industry advisor Helena Mancebo, on 
a regular basis, we were able to avoid this issue for our project. The main 
challenge that we faced is time constraint. As seniors, we are faced with the 
challenge of managing our time efficiently between working on our senior design 
project, finding and securing jobs, completing graduate school applications, and 
working on homework and group projects for classes. As a result, it was 
extremely difficult on occasions for us to do our best work to meet the deadlines 
for specific portions of our senior design project. To address this issue, we 
scheduled regular group meetings and divided up the portions of the project to 
get the assignments completed and turned in on time. It was difficult to meet up 
as a group during the winter quarter because our class schedules were different 
and we were extremely occupied with interviews and outside group projects. As a 
result, we did not work together a lot for the project during the winter quarter 
because the experiments required a large time slot and we did not have a 
timeslot where we were both free. To remedy this issue, we updated each other 
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regularly on the results and alternated with each other in changing the media and 
trypsinizing our cell lines.   
 
The second challenge that we faced is travel to and from the company. It 
became extremely difficult for us to adjust to the long drive to and from Multispan 
Inc., which is headquartered in Hayward, California. We must schedule our 
classes wisely so that we have an ample amount of time to work on our assays 
and to avoid the traffic hours when we are driving down to the company site. As a 
result, we struggled immensely during the first quarter because of the limited 
amount of time that we had to drive up to the company. Molecular biology 
requires a lot of practice on the technique and we didn’t spend enough time the 
first quarter. As a result, our main challenge for the most part is the limited 
amount of time to research, develop adept lab skills, and to carry out 
experiments. Although we had some cell culture experience prior to our project at 
Multispan Inc., we never maintained multiple cell lines over months. The added 
challenge is to maintain multiple cell lines 40 minutes away from where we live. 
Contamination or unhealthy cells would cost both time and money to replace.  
 
2.6.2. Team Budget  
Because we are collaborating with Multispan Inc., on this project, it is fully funded 
by the company because they provide costly cell lines, reagents and chemicals 
for our project. For example, we shouldn’t take more than we actually need of 
chemicals and reagents such as buffer, antibody, and drug compounds because 
those are extremely expensive to waste. This would also push back the project if 
we run out of chemicals and reagents. We also need to take an economical 
approach when we run the experiments and use what we have first. It is not 
logical to purchase the most potent agonist for a GPCR without using the 
alternative agonists in the inventory because it’s guaranteed that the assay will 
work extremely well with the agonist purchased. A detailed breakdown of the 
budget can be found in Appendix   
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2.6.3 Timeline  
It is extremely important to construct and follow a project timeline to ensure that 
the team is staying on top of things. However, it is often rare that the project 
timeline is followed through in every step so the timeline has to be adjusted 
accordingly. The main issue we faced for the timeline is on figuring out exactly 
how much time is required for each specific task. As a result, we decided to 
create an outline by a week-to-week basis which works a bit better for our 
project. For the most part we were on task with the outline for the week-to-week 
tasks but we fell short sometimes because we underestimated the amount of 
time required to complete the task. A detailed outline can be found in Appendix 
B. 
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3.0. SYSTEMS INTEGRATION & VERIFICATION 
3.1. Experimental Protocol  
3.1.1. Expression of Prostanoid Receptors 
Mammalian cells overexpressing the receptor of interest were acquired from 
Multispan’s proprietary cell lines. Human embryonic kidney cells from the HEK 
293T cell line have been modified to overexpress the receptor of interest. Figure 
2 illustrates a general 
structure of this specialized 
cell line. The process of 
receptor overexpression is 
achieved by inserting a 
plasmid containing the 
complementary DNA 
(cDNA) sequence coding 
for the receptor with the 
addition of 24 base pair 
coding for the octapeptide 
FLAG-tag at the N-terminus. Plasmid also included selection markers puromycin 
and ampicillin resistance to ensure the exclusive survival of cells that have taken 
up the plasmid. The translation of this plasmid was ensured by the presence of a 
strong promoter.  
 
3.1.2. Activation of Prostanoid Receptors 
There are three types of receptors in the prostanoid family, inhibitors of 
adenalyse cyclase, contractile and relaxant receptors, with total of eight different 
receptors identified. We have focused on the activation and the subsequent 
internalization of Prostaglandin E Receptor 4 (EP4), Prostaglandin E Receptor 1 
(EP1) and Thromboxane Receptor (TP). Utilizing available literature we have 
identified compounds that activate each of these receptors, known agonists, as 
well as reported EC50 values. We created dilutions of the compounds to 
encompass a wide enough concentration window to achieve acceptable EC50 
Figure 3. Plasmid used to overexpress 
receptor of interest. This process was 
performed at Multispan Inc. 
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values; in this case a 1 in 5 dilution was appropriate. The EP4, EP1 and TP 
receptors were activated with Prostaglandin E2 (PGE2), Iloprost, and 
Prostaglandin D2 (PGD2), respectively. Table 1 below displays the different 
starting concentrations and dilution rates were used for each compound to create 
5x concentrations.  
 
Table 3. Dilutions of the different compounds used for EP1, EP4, and TP. The 
concentrations are in micromolarity with the highest concentration being five 
times as concentrated so that the last dilution step causes the final concentration 
to be 1x.   
Receptor Agonist Dilution 
Rate 
Highest 5x 
Concentration 
(µM)  
Lowest 
[5x] (µM) 
Highest 
[1x] (µM) 
Lowest 
[1x] (µM) 
EP1 Iloprost 1:5 5 3.2 e-4 1 6.5 e-5 
EP4 PGE2 1:5 2.5 1.6 e
-4
 0.5 3.2 e-5 
TP PGD2 1:5 1000 6.4e
-2
 200 1.26e-2 
  
In order to create the appropriate concentrations two steps dilution were made. 
Research compounds are often dissolved in esters. To ensure the solubility of 
the compounds, two steps dilutions were made first into dimethyl sulfoxide 
(DMSO) followed by phosphate buffer saline (PBS). Precautions were taken to 
ensure the final concentration of DMSO in the media during incubation periods 
did not surpass 1% DMSO. The only exception to that is for iloprost because the 
stock compound came in methyl acetate, an alcohol, so 3.5% DMSO is needed. 
To control for the addition of DMSO to the cells the eighth and final well did not 
contain agonist compound and was comprised of DMSO and PBS. This can be 
compared to the seventh well to ensure the values are close. 
 
During the incubation period cells overexpressing the receptors were incubated 
with 40ul of Dulbecco's Modification of Eagle’s Media (DMEM) with 10% Fetal 
Bovine Serum (FBS). Approximately 30,000 cells were placed in each well of a 
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96-well plate.10ul of the 5x dilutions, for a total of 50ul, were then added at 30 
minute intervals ranging from 30 minutes to 120 minutes. The media was then 
removed and washed with PBS three times, ensuring that everything is done on 
ice, before proceeding with staining. 
  
 3.1.3. Tracking of Prostanoid Receptors 
 3.1.3.1. Antibody Staining 
Due to the modification of the GPCR done my Multispan we can track its 
expression on the surface using the Anti-FLAG-tag Antibody that bind to the 
available Flag-tag. Anti-FLAG-tag Antibody (Prozyme α Flag 1.13mg/ml) was 
acquired in 500x concentration. Anti-FLAG-tag Antibody was diluted in PBS to 1x 
concentration and 150ul was added to each well. Cells were placed in a dark 
refrigerator at 2 degrees Celsius for 30 minutes to allow antibodies to bind. Two 
washes were then performed to remove Anti-FLAG-tag Antibodies with PBS and 
one was with PBS + 1% Bovine Serum Albumin (BSA) to prepare samples for 
FACS (Fluorescence-activated cell sorting) analysis.  
 
 3.1.3.2. Analysis of Internalization  
Live cell flow cytometry was performed on the samples to analyze the bind of 
Anti-FLAG-tag Antibodies 
to the available Flag-tags 
on the receptors present on 
the surface of the cell. 
Receptors that have been 
activated and internalized 
will correlate to a decrease 
in the mean fluorescence 
intensity (MFI). Every cell 
passes an interrogation 
point in which the size, complexity and fluorescence are analyzed, we counted 
2,000 of these events and obtained a MFI value for population comparison. 
Figure 4. Loading of the cells overexpressing the 
GPCR of interest on the BD scientific FACsort 
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Figure 5. Histogram showing the the MFI of the parental cells, 
representing our negative control (black), and histogram FLAG tag 
expressing cells prior to the addition of any drug compounds, taken as 
positive control for the experiment (blue). 
Figure 6. Side by side comparison showing how the Anti-FLAG 
tag antibody works on (a) FLAG tag GPCRs and (b) parental 
cells not expressing GPCRS  
Figure 4 illustrates the loading of a sample containing cells overexpressing a 
GPCR receptor and pre-stained with antibody. The instrument used was a BD 
Scientific FACSort and the analysis was run on BD CellQuest Pro software. 
Parent cells in which the overexpressed receptor was induced were first 
analyzed to provide background fluorescence  
 
 
 
 
reading and calibration. The fluorescence in these cells is very low. We can then 
analyze the fluorescence of cells with the overexpressed receptor-Flag-tag 
complex. If the 
cells are 
correctly 
expressing this 
complex then 
the Anti-Flag-
tag Antibody 
will be able to 
bind and cause 
an increase in 
fluorescence.  
FLAG Tag Expressing Cells 
Pre-Activation 
b.  a.  
Negative Control  
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Figure 5 above shows a histogram which includes the MFI for the parental cells 
in black and the Flag tag expressing cells pre-activation. The MFI for the parental 
cells is close to zero because the cells do not overexpress any GPCRs. As a 
result, there is a need to subtract the addition of the parental cell MFI when 
calculating the percentage of internalization. Figure 6a. above illustrates how the 
Anti-flag tags bind to the Flag-tag GPCRs which increase the fluorescence 
intensity. Figure 6b. illustrates how parental cells on attracts little or none of the 
Anti-flag tags which is why the fluorescence intensity should be close to zero. A 
few reasons why the MFI is not zero for the parental cells is due to the error in 
the instrument and a few antibodies clinging to the parental cells.   
 
3.2. Results  
A BD scientific FACSort was used to analyze the mean fluorescence intensity 
(MFI) of our experiments. The data is then plotted on Graph Prism version 4 and 
fitted with a sigmoidal dose response varying slope. Log of the different 
concentrations of the compound is plotted against MFI and In the first 
experiment, we worked with EP4 receptor. We incubated the receptor with 
prostaglandin E2 (PGE2) for 30 and 60 minutes. As observed in Figure 7b. over 
50% internalization is observed during 30 minutes with an EC50 value of 5.21 x 
10-9 M. Triplicate experiment was performed with the error bars representative 
the deviation between each experiment’s concentrations. Figure 7b represents 
the MFI converted to percentage of internalization by first subtracting each value 
by the parental MFI and dividing by the MFI of each concentration by the 
negative control. Figure 7a. and 7c. represents the MFI before the exclusion of 
the parental MFI for each respective time interval. In Figure 7d. over 50% 
internalization is also observed at 60 minutes with an EC50 value of 5.527 x 10
-9 
M. Because the EC50 values of both time points are extremely close to one 
another, we cannot exclude either. The complete plot displaying the all the dose 
response curves can be found in Appendix E.     
 
 
a.  
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 3.2.1. EP4 Internalization  
 
 
 
 
 
 
 
 
 
 
 
 
a.  b.  
c.  d.  
Figure 7. EC50 plots of EP4 internalization at 30 and 60 minutes. (a) & (c)) Log of 
the concentration of PGE2 in molarity is plotted against MFI before the exclusion of 
parental MFI for both 30 and 60 minutes. (b) & (d) represents the log of 
concentration of PGE2 plotted against percentage of internalization. Experiments are 
done in triplicates. 
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 3.2.2. EP1 Internalization 
 
 
 
 
 
In the second set of experiments, we incubated EP1 receptor with iloprost for 60 
minutes. As observed in Figure 8b. over 50% internalization occurred with an 
EC50 value of 4.27 x 10
-10 M. Figure 8a. represents the EC50 value obtained for 
MFI value without the exclusion of the parental cell MFI. The preliminary run 
which includes 30 minutes can be found in Appendix E. 
  
 
 
 
 
Figure 8. EC50 plots of EP1 receptor internalization after 60 minutes. (a) Log 
of concentration of iloprost in molarity plotted against MFI. (b) represents the 
log of concentration of iloprost plotted against percentage of internalization. 
Experiments are done in triplicates with error bars representing deviation 
from each (a) MFI and (b) percentage of internalization.  
a.  b. 
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3.2.3. TP Internalization
 
 
 
 
 
In our last successful experiment, TP receptor was incubated for 120 minutes 
with prostaglandin D2 (PGD2). As observed in Figure 9b. over 40% internalization 
occurred with an EC50 value of 5.95 x 10
-6 M. Figure 9a. represents the EC50 
value obtained for MFI value without the exclusion of the parental cell MFI. The 
preliminary run which includes 30, 60, and 90 minutes can be found in Appendix 
E. 
 
 3.2.4. Unsuccessful Experiments 
Besides the EP1, EP4, and TP1 receptor, we also ran internalization assays for 
EP2, DP1 receptor but little internalization was observed or the experiment was 
not repeatable. The data for these experiments can be found in Appendix E. 
 
 
 
 
 
 
Figure 9. EC50 plots of TP internalization after 120 minutes. (a) Log of 
concentration of iloprost in molarity plotted against MFI. (b) represents the log of 
concentration of iloprost plotted against percentage of internalization. Experiments 
are done in duplicates with the error bars representing deviation from each (a) MFI 
and (b) percentage of internalization 
120 minutes 
120 minutes 
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 3.3. Analysis 
 3.3.1. EP4 Analysis 
With over 50% internalization in 3 separate sets of experiments, the results 
appear to be extremely promising in that the EC50 values fall within 3 fold of each 
other. Our starting point for concentration was based on the International Union 
of Basic and Clinical Pharmacology’s (IUPHAR) database which listed PGE2 as 
having a binding affinity of 9.0 for EP4 for other assays. Internalization assays 
tend to have a higher number and this binding affinity value is converted to the 
negative power of base 10 to derive the exact concentration. As a result, an EC50 
of around 5.17 and 5.53 nM is reasonable. Because the deviation between the 
MFI of each dilution is extremely small, we can conclude that internalization does 
indeed happen within this time window and concentration. Neither 30 nor 60 
minutes can be omitted because of the close proximity between the two EC50 
values.  
 
 3.3.2. EP1 Analysis 
Over 50% internalization is observed in 3 separate sets of experiments and the 
EC50 values of each individual experiment fall within 3 fold of each other. In 
addition, our starting point for this assay was based on both IUPHAR and 
Multispan Inc.’s value for other assays such as calcium and cAMP. Our EC50
 of 
4.27 x 10-10 M value even falls within 3 folds of Multispan Inc.’s EC50 value. None 
of the error bars deviate too much so the assay is validated for this receptor with 
iloprost as the agonist.  
 
 3.3.3. TP Analysis 
We cannot entirely state that this assay has been validated because we were 
only able to reproduce the results in 2 sets of experiments. The deviation in error 
is extremely small which makes this assay promising. The different results 
obtained from the third experiment may be due to pipetting error or slight 
contamination in between. Repeating this experiment will be one of the future 
goals for the group that takes over this project. 
23 
 
4.0 ENGINEERING STANDARDS AND CONSTRAINTS 
 
4.0.1. Social 
It is our duty to ensure that our internalization assays are reproducible with less 
than a 3 fold difference for the drug receptors IC50 and EC50 values. In addition, 
our assay has to be robust with time intervals easily adjustable for testing on 
other drug compounds. Our project does not have any end users outside of our 
testing facilities. We must ensure that others inside of the company can 
reproduce our assays and utilize them for drug discovery much after our 
departure from the company. Once our assays have been optimized it is 
Multispan’s sole responsibility on how these tests are used and to what end 
purposes. This area is beyond our scope of research and we have no control on 
what our assays will be used once optimized. 
 
4.0.2. Ethical 
The ethical ramifications of our project revolves in collaborating with customers 
who have had a good track record and paperwork to prove that their drug 
compounds required for screening are safe and intended for therapeutic medical 
uses. The internalization assays we are attempting to engineer are simply a tool 
used for analysis of data to test for the rate of the drug receptor entering into the 
cell. As a result, it is both the company and our responsibility to ensure that the 
screening of a particular drug target will not lead to unintended consequences 
such as the massive manufacturing of deadly toxins. Our obligation as student 
researchers is to perfect our assays while most of the ethical decisions lies in the 
CEO of Multispan. We have not been required to sign non-disclosure 
agreements; theoretically we can legally share our information and data with 
anyone we please. Ethically, however, we are required to maintain the integrity of 
our research by only sharing information with our advising and funding parties. 
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4.0.3. Manufacturability  
To ensure integrity our internalization assays must be reproducible with at least 3 
individual experiments ran on separate days. In addition, our service has to be 
robust with time intervals easily adjustable for testing on new drugs. Multispan’s 
proprietary technology and assay procedures build upon data from previous 
experiments to confirm the validity of our data. We can also go back to literature 
to ensure we meet the theoretical internalization rates and concentrations with 
known ligands in order to ensure accuracy. Multispan’s proprietary technology 
and assay procedures build upon data from previous experiments to confirm the 
validity of our data. We can also go back to literature to ensure we meet the 
theoretical internalization rates and concentrations with known ligands in order to 
ensure accuracy. 
 
4.0.4 Political 
Experiments are all conducted at company headquarters without the risk of 
outside intrusion. Results will be shared amongst the two of us through Dropbox 
and Google documents as well as with our academic and industry advisors. No 
one else should know or have access to our data and research without implicit 
consent from Multispan Inc. Errors is to be expected and necessary to report and 
for conducting proceeding experiments. Without reporting errors, similar ones 
may appear again in the future. All of our data, whether valid or not, should be 
shared amongst ourselves and made our advisors aware of its existence. No 
data should go without being questioned and analyzed. 
 
4.0.5. Safety 
The physical risks of our project are minimal. However, we must focus on 
confidentiality. Each specific ligand/ receptor is unknown to us because they 
are proprietary compounds from customers of Multispan. They don’t know nor 
are they allowed to know. Physical safety is not exactly a factor in this project 
but we are dealing with chemicals in a lab setting which may be flammable 
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and toxic. Therefore, we must observe good laboratory practice. The 
confidentiality of this project revolves among the two of us working on it and the 
company itself. It would then be up to the company's dissection who it shares our 
findings with. 
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6.0. Summary and Conclusion  
 
Initially our project goal was to develop internalization assays for the entire 
prostanoid family. Realistically, this was improbable as our team did not have 
prior biochemistry background before the project. However, we did not imagine 
that it would be such a difficult task to validate three receptors for agonist 
response. The difficulty comes in the constraints of the available literature 
research on the internalization of prostanoid receptors and which compounds we 
have available at Multispan Inc. In addition, time was a significant limiting factor 
as we were balancing between classes, projects, job applications, extracurricular 
activities, and senior design. We were well aware that the tradeoff of running 
Multispan Inc.’s platform would be time consuming but the tradeoff would be 
accuracy to the level of individual cells.  
 
In regards to the receptors which did internalize, over 50% internalization was 
observed for EP4 and EP1 by being activated by PGE2 and iloprost respectively. 
EP4 internalized over the time intervals of 30 and 60 minutes with an EC50 value 
of 5.2 nM and 5.6 nM respectively. Because both of the EC50 values fall so close 
to each other, we cannot dismiss either time points. Most importantly, the EC50 
value falls within the range of other assays, the deviation in MFI is extremely low 
for each dilution of the drug, and the experiment is performed in triplicates. For 
EP1, the receptor internalized after 60 minutes after being activated by iloprost. 
The experiment is validated because it falls within range of the values presented 
for both IUPHAR and Multispan Inc.’s database for other assays. In addition, the 
results were reproducible in 3 experiments. In the third experiment, we observed 
over 40% internalization for the TP receptor after 120 minutes. It was extremely 
difficult to find literature research on TP internalization and Multispan Inc. did not 
have any of the known potent agonists. As a result, we took a bit of a risk and 
chose PGD2 with the knowledge of its binding affinity value and chose a starting 
concentration accordingly. We were able to successfully replicate the experiment 
twice with an extremely small deviation between the MFI for different 
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concentrations of the drug compound. More importantly, the EC50 value falls a 
little over the converted value listed from IUPHAR for other assays. Because we 
were unable to repeat this experiment a third time, we cannot completely state 
that the assay is validated but at the same time we cannot completely dismiss 
the results.  
 
Besides EP1, EP4 and TP, we also ran EP2 and DP1 assays but we were 
unsuccessful in our attempt to internalize the receptors. For the most part in the 
beginning of the project, we struggled on technique so our results for EP2 was 
not logical at all. The drug we used for EP2 was iloprost because it was actually 
the protocol initially developed by Dr. Venkhat. We did not attempt to internalize 
the receptor again until the spring quarter. The results showed very little 
internalization with iloprost when we ran it again. For DP1, we were initially able 
to obtain some promising results with over 30% internalization but the results 
were not repeatable the second time. This may be due to many factors such as 
unhealthy cells, inconsistent technique, or the drug compound may have been 
contaminated.  
 
In the future, we hope that the individuals who continue this project obtain the 
IC50 values for EP1 and EP4 receptors. In addition, we would hope that the next 
group would repeat our TP assay experiment and finish the validation and move 
on to obtaining IC50 values. By obtaining the IC50 value, we will then have the 
complete assay for each receptor to test on libraries of compounds.  
 
Up to this point, we have been able to utilize Multispan’s proprietary cell lines to 
overexpress a few GPCRs. We have activated EP1, EP4, and TP with iloprost, 
PGE2, and PGD2. In turn, we were able to obtain EC50 values and specific time 
intervals for receptor internalization. With these assays we are attempting an in 
vitro model of an agonist dose response. These assays monitor receptor 
activation and internalization. In turn, they become powerful tools for the 
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discovery of novel therapeutics to test against libraries and to screen from a few 
thousand to millions of compounds.  
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7.0 APPENDICES 
7.1 Customer Needs Survey 
 
Interviewer: William Truong 
Method: E-mail 
Dr. Helena Mancebo, CEO Multispan Inc.  
 
1. Who are Multispan’s competitors for the internalization assays? 
-No one else is offering internalization assay that we know of. 
 
2. What are Multispan’s prices per internalization assay for companies?  
-We can’t really share pricing information. It’s privileged information between Multispan 
and its customers 
 
3. Is time a factor that is weighed heavily for the internalization assays? 
It’s all driven by biology---i.e. How long it takes for measurable amount of each receptor 
to be internalized following receptor activation. 
 
4. During this internship at Multispan, what will be required for Josergio and I? 
You will need to perform the following: 
1.       Learn and perfect cell culture, FACS, and assay development techniques. 
2.       Independently plan and carry out experiments from start to finish. 
3.       After each experiment, critically analyze data, troubleshoot and design the follow-
up experiments. 
4.       Perform literature search, deepening understanding in receptor protein turnover 
and trafficking. Seek advice regularly by asking prepared questions. 
6.       Apply rigor and diligence to your work at all levels. 
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5. What are the requirements for the results of each internalization assay 
(customer’s perspective)? 
1. Reproducibility: Each assay need to be shown with less than 3 fold differences 
EC50s or IC50s in 3 independent experiments to be considered “validated”. 
2. Timeline: Develop validated internalization assays for all targets within each assigned 
receptor family by the end of the project. 
  
Interviewer: William Truong 
Method: In-Person 
Dr. Ricai Han, Senior Scientist Multispan Inc. 
 
1. Is Multispan aware of any specific information regarding the drugs sent by the 
companies such as Johnson and Johnson? 
Multispan does not know the affinity of the receptor or other specific information about it. 
We also don’t know whether compound could affect trigger signal transduction. 
 
2. Without knowing any specifics about the drugs, what does a researcher need 
to do in order to perform these internalization assays? 
We need to characterize the function and activities of how it would affect surface 
expression. In addition, we need to find the internalization factor. 
 
3. What is expected of us after we are able to report an internalization assay for 
one GPCR receptor? 
After completing this task we may move onto other assays like cAMP, Beta etc.  
 
4. As a scientist, what is your take on weighing in time as an important variable 
for these experiments? 
It is desired but probably not yet achievable for speeding up the time of internalization 
for each receptor.  Each internalization time varies based on the receptor type.  
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Interviewer: William Truong, Josergio Zaragoza  
Method: In-Person  
Dr. Radhika Venkhat, R & D Manager, Multispan Inc.  
 
1. Can you share with us your experience with internalizing receptors? 
-I have worked with many GPCRs for internalization but for your assigned family, I have 
only worked with DP2.  
 
2. What issues did you face during your internalization assays? 
The first issue is framing the time point of internalization for an unknown compound with 
a receptor. The reason is that there is a rapid recycling time frame for some receptors 
and it is essential to grasp this specific time interval in order for us to not miss the point 
of internalization. 
  
3. How do you determine the agonists and antagonists that are used for each 
assay? 
 Agonists and antagonists are chosen base on those reported from literature research 
and analysis. Some internalization is derived from external factors. Others may require 
internalization with other receptors (Ex: some articles have noted that EP2 internalizes 
with EP4.  
 
4. What signaling pathways did you utilize during your internalization assays? 
I only checked on surface independent pathway not overexpressing receptors. I did not 
check the dependent downstream signaling pathway. 
 
5. What is your advice in your approach towards coming up with an 
internalization assay for our families of receptors? 
Keep practicing on the technique and running the assays. Once you master the 
technique and read more on the literature you would then learn whether there’s a need 
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to increase or decrease drug concentration and whether the time intervals need to be 
shorter or longer. 
7.1.1 Detailed Product Design Specification 
Table A-1. Detailed product design specification breaking down three main categories: 
assay, confidentiality and deliverables.  
Category Requirement Importance 
 
 
 
 
 
 
 
Assay 
EC50,IC50 must be found 
to be accurate within a 
threefold difference 
 
 
Validated internalization 
assay for all targets in 
prostanoid Family  
 
 
Assay must be 
reproducible in 3 individual 
runs   
 
 
High- The minimum threshold of 
internalization of the receptor 
with any given agonist must be 
accurately determined for the 
assay to be valid. 
 
Med-Low- Some receptors in 
our family may require external 
factors or co-internalization with 
another receptor in order to 
internalize which is out of our 
abilities. Not all receptors in all 
families have been identified, 
studied, or found. 
High- In order to cut down on 
time, costs, and to have 
complete validation this must be 
true  
 
 
 
Confidentiality  
Proprietary procedures, 
materials and information 
must remain within 
Multispan Inc. 
 
 
Ligand affinity and 
properties provided by 
other companies will not 
be known and should not 
be investigated for 
High- All recombinant cells and 
reagents must remain inside the 
company. Procedures should not 
be shared with individuals 
outside of advisors.  
 
Low- It is not very likely that we 
will be working with outside 
ligands. The properties of these 
ligands will not be provided. 
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purposes outside assays.  
 
 
Deliverables Data must be complete and 
under final conditions for two 
receptor families  
High- Any discrepancies between the 
data will cause doubt in the user and 
there needs to be controlled and 
monitored conditions  
 
7.1.2. Detailed Budget Breakdown  
Table A-2. Detailed budget breakdown and costs of the materials, including the vendor, 
quantity, unit, and description of the item used for research.  
 
Vendor Description Price Unit  Quantity  Cost  
VWR 15 mL conical tubes 68.00 500/case 1 $79.75 
VWR 96-Well Plates, 
Polypropylene, V-
Bottom 
106.6
4 
100/case 1           
$144.51  
BD 
Bioscience
s 
Calibrite 3 color beads 257.5
0 
1 box 1            
$318.09  
VWR Nonsterile reservoirs 46.64 100/case 1 $78.90     
VWR Hyclone FBS 169.8
4 
1 bottle 3 $541.78 
VWR 2 mL pipets 50.38 500/case 1   $59.99             
VWR 10 mL pipets 27.85 200/case 1 $37.46       
VWR Trypsin 33.00 6x100mL/pac
k 
1   $52.59 
Invitrogen Gibco DMEM w/ 
GlutaMAX 
196.7
8 
1 case 
(10x500mL) 
1            
$230.87  
VWR 10 mL pipets 27.85 200/case 1    $41.93  
VWR Dialyzed FBS (hyclone) 385.3
9 
500 mL 3 $1,234.9
3        
VWR Cryovials 100.3
5 
500/case 1 $179.11 
VWR Eppendorf* Safe-Lock 
Polypropylene, 0.5 mL 
40.80 500/case 1             
$47.31  
VWR P1000 tips, with filter, 
sterile 
44.00 768/pack 1             
$66.25  
VWR T-25 flasks 67.85 100/case 1             
$90.10  
VWR 25 mL pipets 68.00 200/case 1             
$90.25  
VWR 6-well plates 57.50 50/case 1             
$79.75  
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VWR 96-well plates 67.00 50/case 1              
$89.25  
VWR 15 mL conical tubes 68.00 500/case 1             
$90.25  
Office 
Depot 
Bleach 2.96  1 $3.48              
VWR DMEM 35.94 6/pack 6 $223.09 
VWR PBS 1X W/O CA+MG 
6X500ML 
35.94 6x500 mL 1              
$43.39  
VWR 5 mL pipets 26.60 200/case 1              
$44.48  
VWR Sterile reservoirs 95.39 100/case 1 $106.74 
VWR T-75 flasks 63.20 60/case 1 $77.70 
VWR medium Nitrile gloves 132.7
9 
1000/case 1 $144.14 
VWR Universal Fit Tips, Low 
Retention (p20) 
104.0
0 
4800/case 1           
$117.53  
VWR 96-Well, U-Bottom 
Assay Plate 
125.4
7 
50/case 1           
$139.30  
VWR DME/F12 media 8.2 500 mL/each 6 $59.38 
VWR Aspirating pipets 30.20 200/case 1 $40.38 
VWR P20, P200 refills 18.60 960/pack 1 $28.78 
VWR P1000 tips, no filter, 
non-sterile 
10.00 576 tips/pack 1             
$20.18  
VWR Conical-Bottom 
Centrifuge Tube with 
Flat Cap, 50 mL 
80.34 500/case 1             
$88.37  
ProZyme anti-FLAG-RPE 
Conjugate (FACS Ab) 
650.0
0 
1 mg/vial 2         
$1,403.0
0  
BD BD FACSFlow Sheath 
Fluid 
31.00 20 L/each 3             
$93.00  
 Total Expenses     $6,185.9 
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7.2 Glossary of Terms  
Ligand: substance that binds to a chemical entity to form a larger complex  
Agonist: chemical that binds to a receptor and triggers a response 
Antagonist: ligand that blocks or dampens agonist-mediated responses 
EC50: dosage (concentration) which produces 50% of a maximum given effect  
IC50: half maximal inhibitory concentration of a compound to inhibit a biological or 
biochemical effect  
Internalization: endocytosis (when cell engulfs molecule or receptor) of GPCR 
Clathrin: protein that plays a major role in the formation of vesicles  
Arrestin: small family of proteins important for regulating signal transduction 
Flow Cytometry: technique for counting and examining microscopic particles by 
suspending them in a stream of fluid and passing them through an electronic detection 
zone 
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7.3. Project Management Timeline 
Fall Quarter 
Week 5:  
 Continue training on cell culturing and shadow Dr. Venkat on cell assay 
techniques 
 Write up budget proposal to submit to both senior design and engineering 
department for grant 
 Continue looking up literature research for prostanoid receptors 
 Learn how to use the live cell flow cytometer 
 Run first GPCR internalization assay Friday one of our receptors of interest 
 Send e-mails or meet up with Researchers for customer needs report 
Week 6: 
 Review Internalization Assay procedure and notes  
 Continue Literature research on the internalization procedures done on two 
interested families of receptors (EP1 and EP2) 
 Work on Customer needs report to submit Friday 
 Practice using FACS machine  
 Learn how to use FACS software  
Week 7:  
 Meet up with Dr. Mancebo and Dr. Zhang to talk about our progress and clear up 
direction for project 
 Gather literature research and come up with protocol for internalization assay 
 Go over internalization protocol with Dr. Venkat and work on skills required for 
assay 
 Start working on CDR draft 
Week 8: 
 Continue literature research on EP1 and EP2 and decide whether these two 
receptors are viable starting point. 
 Continue practice with FACS machine, internalization assays and begin looking 
into protocols for cAMP assays if needed  
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 Finish CDR draft and turn in Friday 
 
Week 9: 
 At this point we should be really familiar with cell culture , passaging of the cells, 
and become more comfortable with working on internalization assays 
 Come up with an alternative method such as modifying agonist or antagonist 
receptors if internalization assay was not successful for the two target GPCRs up 
to this point. 
 Decide whether or not to move on to another receptor family and receive 
feedback from our two advisors 
 Start practicing for presentation 
Week 10:  
 Trouble shooting/catch up week  
 Continue literature research and move on to another prostanoid receptor to 
prepare for next quarter 
 Presentation slide package due 
 Wrap up experiment and submit results and work throughout quarter to adviser to 
see what direction we need to head to next quarter 
 Work on CDR draft to submit  
Week 11: (Finals Week) 
 Follow up on any work that needs to be completed 
 Begin scheduling for working times for next quarter 
 Review over data to see if there is a need to rerun any experiment  
 Perform research on prostanoid receptor pathway of choice and start on a 
protocol for Andy and Dr. Mancebo to review before heading off to break 
 
Winter Quarter: 
 -Start on internalization assays on different receptor of interest  
 -Work on detailed drawings due near middle of quarter 
 -Work on assembly drawings and initial hardware due end of quarter 
 -Work on presentations for senior design 
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 -Work on Poster for engineering events if we are funded by engineering 
 -Start developing internalization assays on different receptors of interest  
 -Work on and finish end of quarter report 
 -Plan schedule for spring quarter and set up new meeting times for working at 
Multispan and meetings with advisor  
  
Spring Quarter: 
 -Work on the finalization stages of our assay development  
 -Continue practicing on public speaking skills for presentation  
 -Finalize data and results and work on additional receptors if ample time is left 
and enough literature research is obtained to support assay analysis 
 -Prepare for senior design conference 
 -Start early on putting together senior design thesis 
 -Prepare poster board for open house 
 -Finalize slides for senior design presentation 
 -Reserve the last day before the presentation to relax and be ready for the 
presentation  
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7.4. Extra Experiments  
 7.4.1. EP1 
 
  
 
 
  
 7.4.2. EP4 
 
 
 
 
 
Figure A. Preliminary EC50 plot for EP1 which includes 30, 60, and 90 minutes.  
 
Figure B. Preliminary EC50 plot for EP4 which includes 30, 60, 90, and 120 minutes.  
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7.4.3. DP1
 
 
 
 
 
 
 
 
 
 
Figure C. DP1 EC50 plot which shows only 90 min and 120 minute. Dose response 
curve cannot be fitted for 30 and 60 minutes.  
 
